What did @slc_medspa actually say?
The creator held up a small pellet and told viewers that this "biotechnical estradiol" insert, placed under the skin of the hip, would make mental fog, hot flashes, and joint pain disappear. She tied it directly to GLP-1 weight loss, claiming that "when you lose that belly fat... the fat stays away." She also said flat out: "You know this is safe. It's the very best thing you can do for your health."
That last line is doing a lot of work. Estradiol pellets are a real, physician-prescribed hormone therapy option, but framing any single intervention as "the very best thing you can do for your health" is a marketing claim dressed up as medical advice. The audience watching a 454K-view Instagram reel deserves more nuance than that.
Does the science back this up?
On the core symptoms, yes, broadly. But the pellet delivery method and the certainty of the claims deserve scrutiny.
Estrogen therapy is among the best-studied treatments for vasomotor symptoms like hot flashes. The 2022 Menopause Society (NAMS) position statement confirms that hormone therapy is effective for hot flashes, sleep disruption, and joint pain in perimenopausal and postmenopausal women. That part checks out.
The "mental fog" claim is more complicated. There is evidence that estrogen supports cognitive function during the menopausal transition. Maki and Henderson (2016, Seminars in Reproductive Medicine) found that estrogen therapy started near menopause onset may reduce cognitive symptoms, but the timing and duration matter significantly. This is not a guaranteed outcome.
On pellets specifically: subcutaneous pellet delivery is not FDA-approved for estradiol in the way oral or patch formulations are. Most pellets are compounded. A 2019 review by Stuenkel in Climacteric noted that pellet therapy produces highly variable serum estradiol levels, with some patients reaching supraphysiologic concentrations. "Supraphysiologic" is not a synonym for better.
What did they get wrong (or right)?
Credit where it is due: the symptom list she rattled off (hot flashes, brain fog, joint pain, weight redistribution) is clinically real and undertreated. Women are routinely undertreated for menopausal symptoms. That part of the message is legitimate and worth saying loudly.
Where she goes wrong is in the absolutism. Saying "you know this is safe" about a compounded pellet product glosses over real concerns. The FDA has specifically flagged compounded bioidentical hormones, noting in a 2022 statement that they lack the safety and efficacy data of approved products. Physicians cannot simply transfer the safety record of FDA-approved estradiol to compounded pellet versions.
The GLP-1 combination claim, that hormone therapy keeps the fat off after GLP-1-driven weight loss, is plausible as a hypothesis but is not backed by robust randomized controlled trial data. It is being presented as settled fact to a lay audience, and it is not.
Calling a 15-minute appointment every four months the entry point to this therapy also undersells the monitoring required. Pellet dosing requires follow-up lab work to avoid supratherapeutic estradiol levels.
What should you actually know?
Hormone therapy for menopausal symptoms is legitimate medicine. If you are struggling with hot flashes, poor sleep, joint pain, or cognitive changes during perimenopause or menopause, talking to a physician about hormone therapy is reasonable and supported by evidence. The NAMS 2022 guidelines explicitly state the benefits outweigh the risks for most healthy women under 60 within 10 years of menopause onset.
However, the delivery method matters. Pellets are not FDA-approved and produce less predictable hormone levels than patches or low-dose oral estradiol. Cynthia Stuenkel's work in Climacteric (2019) flagged that pellet patients can run estradiol levels several times above the normal therapeutic range, which raises questions about long-term safety that have not been fully answered.
If you are considering this, ask your provider to show you serum estradiol levels before and after insertion, understand the compounded versus FDA-approved distinction, and do not treat a 15-minute appointment as sufficient ongoing care. Good hormone management is iterative. It involves labs, symptom tracking, and dose adjustment over time.